Skip to main content


Medical Specialties > Structural Heart > TVT 2021 Clinical Presentation


12 SITES  |  N = 554 PATIENTS


The Early neo2 Registry is an investigator-initiated and conducted, single arm, multicenter registry that assessed the ACURATE neo2 Aortic Valve System’s performance.1

Echocardiographic images of 85% of the Early neo2 Registry patients were analyzed by an echocardiographic core-lab analysis and presented by Dr. Andreas Rück from the Karolinska Institute (Stockholm, Sweden) at TVT, 2021. View the presentation.2



The ACURATE neo2 Valve performed consistently for key patient outcomes:

Coronary Access
stroke icon
Complication Rates
Complication Rates
* Post-procedure echo. Core-Lab assessed site-reported; † In-Hospital; ‡ 30-Days; § Procedural




Percent of evaluable echocardiograms demonstrating post-procedure PVL rates from the core-lab adjudicated Early neo2 Registry.2

Active PVseal